Latest Insider Transactions at Acrivon Therapeutics, Inc. (ACRV)
This section provides a real-time view of insider transactions for Acrivon Therapeutics, Inc. (ACRV). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Acrivon Therapeutics, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Acrivon Therapeutics, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 14
2023
|
Kristina Masson EVP - Business Operations |
SELL
Payment of exercise price or tax liability
|
Direct |
1,900
-0.59%
|
$9,500
$5.08 P/Share
|
|
Nov 14
2023
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
735
-1.75%
|
$3,675
$5.08 P/Share
|
|
Oct 17
2023
|
Mary Miller Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,232
-5.04%
|
$11,160
$5.48 P/Share
|
|
Sep 26
2023
|
Mary Miller Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,858
+8.01%
|
-
|
|
Aug 21
2023
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
493,994
+14.56%
|
-
|
|
Jun 26
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
16
-0.0%
|
$192
$12.93 P/Share
|
|
Jun 16
2023
|
Rasmus Holm Jorgensen Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,500
+24.34%
|
$28,500
$3.63 P/Share
|
|
Jun 15
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,056
-0.05%
|
$24,672
$12.14 P/Share
|
|
Jun 14
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
893
-0.02%
|
$10,716
$12.13 P/Share
|
|
Jun 13
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
3,000
-0.08%
|
$36,000
$12.3 P/Share
|
|
Jun 12
2023
|
Chione LTD > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
2,000
-0.05%
|
$24,000
$12.34 P/Share
|
|
Jun 05
2023
|
Eric Devroe Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,225
+12.79%
|
$9,225
$1.04 P/Share
|
|
May 31
2023
|
Peter Blume Jensen President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
33,605
+1.38%
|
$100,815
$3.88 P/Share
|
|
Nov 17
2022
|
Chione LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
3,456,597
+23.73%
|
-
|
|
Nov 17
2022
|
Chione LTD > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
400,000
+9.4%
|
$4,800,000
$12.5 P/Share
|
|
Nov 17
2022
|
Ra Capital Management, L.P. |
BUY
Conversion of derivative security
|
Indirect |
1,421,008
+50.0%
|
-
|
|
Nov 17
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
3,389,500
+43.6%
|
$40,674,000
$12.5 P/Share
|
|
Nov 17
2022
|
Wellington Biomedical Innovation Master Investors (Cayman) I L.P. |
BUY
Conversion of derivative security
|
Direct |
888,130
+50.0%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Indirect |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Peter Blume Jensen President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Indirect |
1,498,240
+18.15%
|
-
|
|
Nov 14
2022
|
Kristina Masson EVP - Business Operations |
BUY
Grant, award, or other acquisition
|
Direct |
26,707
+7.69%
|
-
|
|
Nov 14
2022
|
Rasmus Holm Jorgensen Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|
|
Nov 14
2022
|
Eric Devroe Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
33,383
+38.35%
|
-
|
|
Nov 14
2022
|
Erick Gamelin Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
20,030
+50.0%
|
-
|